Cipla's etanercept up to new Indian guidelines?
This article was originally published in Scrip
Executive Summary
In an unusual move, an Indian biotechnology industry body has fired off a letter to the Drugs Controller General of India, asking whether Cipla's recently launched cut-price etanercept, a biosimilar version of Amgen's Enbrel, meets certain criteria laid down in the country's new guidelines for such products.